Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm Journal Article

  


Authors: Chi, D. S.; Eisenhauer, E. L.; Zivanovic, O.; Sonoda, Y.; Abu-Rustum, N. R.; Levine, D. A.; Guile, M. W.; Bristow, R. E.; Aghajanian, C.; Barakat, R. R.
Article Title: Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
Abstract: Objective: To determine the impact on progression-free survival (PFS) and overall survival (OS) of a programmatic change in surgical approach to advanced epithelial ovarian cancer. Methods: Two groups of patients with stage IIIC and IV ovarian, tubal, and peritoneal carcinoma were compared. Group 1, the control group, consisted of all 168 patients who underwent primary cytoreduction from 1/96 to 12/99. Group 2, the study group, consisted of all 210 patients who underwent primary surgery from 1/01 to 12/04, during which time a more comprehensive debulking of upper abdominal disease was utilized. Results: There were no differences between the groups in age, primary site of disease, surgical stage, tumor grade, American Society of Anesthesiologists class, preoperative serum CA-125 and platelet levels, percentage with or amount of ascites, size or location of largest tumor mass, or type of postoperative chemotherapy. Patients in Group 2 vs Group 1 more frequently had extensive upper abdominal procedure(s) (38% vs 0%, respectively; P < 0.001) and cytoreduction to residual disease < 1 cm (80% vs 46%, respectively; P < 0.01). Five-year PFS and OS rates were significantly improved in Group 2. For Group 2 vs Group 1 patients, 5-year PFS rates were 31% vs 14%, respectively (hazard ratio, 0.757; 95% CI, 0.601-0.953;P = 0.01]; and 5-year OS rates were 47% vs 35%, respectively (HR, 0.764; 95% CI, 0.592-0.987;P = 0.03]. Conclusion: The incorporation of extensive upper abdominal procedures resulted in increased optimal cytoreduction rates and significantly improved PFS and OS. A paradigm shift toward more complete primary cytoreduction can improve survival for patients with advanced ovarian, tubal, and peritoneal carcinomas. © 2009 Elsevier Inc. All rights reserved.
Keywords: survival; controlled study; disease-free survival; survival rate; major clinical study; overall survival; disease free survival; combined modality therapy; cancer staging; neoplasm staging; cancer grading; ovarian cancer; cytoreductive surgery; ovarian neoplasms; multiple cycle treatment; ovary cancer; peritoneum cancer; surgical approach; time factors; survivors; minimal residual disease; thrombocyte count; taxoids; ca 125 antigen; cytoreduction; debulking; platinum complex; taxane derivative; uterine tube carcinoma; platinum compounds
Journal Title: Gynecologic Oncology
Volume: 114
Issue: 1
ISSN: 0090-8258
Publisher: Elsevier Inc.  
Date Published: 2009-07-01
Start Page: 26
End Page: 31
Language: English
DOI: 10.1016/j.ygyno.2009.03.018
PUBMED: 19395008
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-67349224121&partnerID=40&md5=3e08c30a87837e71f4571e99693399c8
Notes: --- - "Cited By (since 1996): 20" - "Export Date: 30 November 2010" - "CODEN: GYNOA" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Richard R Barakat
    629 Barakat
  2. Dennis S Chi
    707 Chi
  3. Yukio Sonoda
    472 Sonoda
  4. Douglas A Levine
    380 Levine
  5. Nadeem Abu-Rustum
    888 Abu-Rustum
  6. Eric Eisenhauer
    36 Eisenhauer
  7. Oliver Zivanovic
    291 Zivanovic
  8. Carol A Aghajanian
    607 Aghajanian
Related MSK Work